KEYNOTE-905 (EV-303): NCT03924895: Phase 3: Periop Pembro + Cystectomy or Periop Pembro + Enfortumab Vedotin + Cystectomy Versus Cystectomy Alone in (Cis ineligible) Muscle-invasive Bladder Cancer
First Posted 2019-04-23 Trial status Active, not recruiting Sponsor Merck Sharp & Dohme LLC Abstract Presentation Phase 3 KEYNOTE-905/EV-303: Perioperative pembrolizumab (pembro) or pembro + enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC). 2023 ASCO Genitourinary Cancers Symposium Click here for details Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin
Dec 18, 2025
KEYNOTE-A39 : NCT04223856: Phase 3: Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (EV-302)
First Posted 2020-01-10 Trial status Active, not recruiting Sponsor Astellas Pharma Global Development, Inc. Abstract Presentation Survival Benefit of Enfortumab Vedotin and Pembrolizumab Compared with Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer ESMO - 11 Mar 2024 Click here for details Peer-reviewed journal publication Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer March 6, 2024 - N Engl J
Dec 15, 2023
HER2CLIMB: NCT02614794: Phase 3: Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer
First Posted 2015-11-25 Trial status Completed Sponsor Seagen Inc. Abstract Presentation Phase III HER2CLIMB Trial Yields Positive Data in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastasis Late-breaking oral presentation, San Antonio Breast Cancer Symposium 2019; results subsequently published in NEJM (2020). Click here for details Peer-reviewed journal publication Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer Dece
Dec 15, 2020